Sponsors (33)
Official title: To increase access to pre-exposure prophylaxis to reduce the transmission of HIV.
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
The bill greatly expands affordable access to HIV prevention and funds outreach and enforcement to reduce disparities, but it does so at higher federal/state and insurer costs, with added administrative burdens, privacy and litigation risks, and questions about long‑term sustainability.
Millions of people with or at risk for HIV — including private plan enrollees, Medicare, Medicaid/CHIP beneficiaries, veterans, TRICARE/VA patients — will get FDA‑approved HIV prevention drugs, associated labs, and follow‑up care with no cost‑sharing, lowering out‑of‑pocket costs and financial barriers to prevention.
Uninsured, underinsured, and safety‑net populations will gain access to PrEP/PEP through federally funded programs, navigators, and provider support, improving coverage for people who currently lack affordable options.
Targeted outreach, public education, and clinician training — with community engagement and cultural competency requirements — will increase PrEP/PEP awareness and clinician offer rates in communities disproportionately affected by HIV, helping reduce transmission and disparities.
Federal, state, and program spending will rise — expanding no‑cost coverage, new grant programs, outreach campaigns, and programmatic responsibilities increases costs for taxpayers and state budgets.
Insurers and public programs will face higher drug and administrative costs that could be passed to consumers through higher premiums or contribute to fiscal pressure on Medicaid/other programs.
New and expanded reporting, compliance, and system changes will impose administrative burdens and costs on insurers, states, small providers, and plan administrators (including 10‑year reporting obligations), which may be especially heavy for small practices and nonprofits.
Based on analysis of 20 sections of legislative text.
Requires private plans to cover FDA‑approved HIV prevention drugs and related services without cost‑sharing, bans most prior authorization, funds education and grants, protects confidentiality, and creates a private right of action.
Requires private group and individual health plans to cover FDA-approved HIV prevention drugs (PrEP and PEP) and related clinical services without cost-sharing and generally without prior authorization. Creates federal education campaigns, a grant program to expand PrEP/PEP access for uninsured and underinsured people, strengthens privacy so family-plan use of these preventive services is confidential, bans discrimination by life/disability/long‑term care insurers for people using HIV prevention medication, and creates a private right of action for enforcement.